LEDGER STEVEN A 4

What Happened
Steven A. Ledger, CEO of Serina Therapeutics (SER), was granted/acquired 10,100 shares on May 26, 2026. The filing reports a weighted-average acquisition price of $1.93 per share, for an aggregate value of approximately $19,493. This transaction is reported as an award/grant (transaction code A), an acquisition rather than a sale.

Key Details

• Transaction date: 2026-05-26; Form 4 filed: 2026-05-27 (timely).
• Reported price: weighted average $1.93 per share (range $1.87–$1.95 across multiple transactions; see footnote).
• Shares acquired: 10,100; aggregate value reported: $19,493.
• Shares owned after transaction: not disclosed in this filing.
• Footnote: the price is a weighted average of multiple purchase prices ($1.87–$1.95). Upon SEC request, the filer will provide the breakdown by price.
• No 10b5-1 plan, tax-withholding, or cashless exercise notation was reported.

Context
This was a stock award/grant to the CEO (an acquisition), which increases insider ownership but does not by itself indicate future performance. Because this is an award rather than a sale, many investors view it differently than routine disposition filings; however, no motives or future plans are disclosed.